<SEC-DOCUMENT>0001104659-26-024121.txt : 20260305
<SEC-HEADER>0001104659-26-024121.hdr.sgml : 20260305
<ACCEPTANCE-DATETIME>20260305161546
ACCESSION NUMBER:		0001104659-26-024121
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20260305
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260305
DATE AS OF CHANGE:		20260305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NextCure, Inc.
		CENTRAL INDEX KEY:			0001661059
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				475231247
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38905
		FILM NUMBER:		26726333

	BUSINESS ADDRESS:	
		STREET 1:		9000 VIRGINIA MANOR ROAD, SUITE 200
		CITY:			BELTSVILLE
		STATE:			MD
		ZIP:			20705
		BUSINESS PHONE:		240-399-4900

	MAIL ADDRESS:	
		STREET 1:		9000 VIRGINIA MANOR ROAD, SUITE 200
		CITY:			BELTSVILLE
		STATE:			MD
		ZIP:			20705
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nxtc-20260305x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.2.0.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/5/2026 6:17:30 PM -->
<!-- iXBRL Library version: 1.0.9448.42501 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nxtc="http://nextcure.com/20260305" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>NextCure, Inc._March 5, 2026</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:EntityCentralIndexKey" id="Tc_XOUQAewLeUi6qi4jS3fdZg_2_1">0001661059</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:AmendmentFlag" id="Tc_Q4u6uM_Cx0uRN9GIvwlpxw_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="nxtc-20260305.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-05</xbrli:startDate><xbrli:endDate>2026-03-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:735.25pt;"><div style="height:22.5pt;left:0%;position:absolute;top:712.75pt;width:468pt;z-index:251658240;"><div style="height:21.6pt;left:0pt;padding-bottom:0.9pt;position:relative;top:0pt;width:468pt;"><div style="height:21.6pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:468pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:8pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><a id="_afc943fc_0c9e_4123_8c37_61dd1e2923fb"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;">UNITED STATES</b><b style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;"><br/></b><b style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:18pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:DocumentType" id="Narr_rBxf571z-U6EaCD5I0OPUw"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">CURRENT REPORT</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br/></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_Lh3CRSkCfUO-ZoABJF3n1A"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">March 5, 2026</span></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:18pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:EntityRegistrantName" id="Narr_l_31-DbIIE2SDlzdoN6r_g"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NextCure, Inc.</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(Exact name of registrant as specified in its charter)</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Narr_V05w5aT3xku3LA1ofChQbw"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">Delaware</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"><br/></b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(State or other jurisdiction of incorporation)</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:EntityFileNumber" id="Narr__7d_6k6HF0ud4cfvZ5JU3g"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">001-38905</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"><br/></b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(Commission File Number)</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:EntityTaxIdentificationNumber" id="Narr_RMGyzKYe9Uu8OMME6m-JCw"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">47-5231247</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"><br/></b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(IRS Employer Identification No.)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><a id="_2aff84aa_b833_42e6_86ca_720304bb3c4b"></a><a id="Tc_U7wXHgD6uUCJ1oaCozvY9w_1_0"></a><a id="Tc_QspYdQ17L0GdR6hKoz_DrQ_2_0"></a><a id="Tc_EXXZv3LoE0KnTMs4CddVog_2_2"></a><a id="Tc_pV5MLQ6mHk-M3MuGbBbymw_3_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:EntityAddressAddressLine1" id="Narr_sduoItm1wUiPpilFpD3d-w"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">9000 Virginia Manor Road</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:EntityAddressAddressLine2" id="Narr_XgT7Mx21XEOOY9bwaPMDDA"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">Suite 200</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:EntityAddressCityOrTown" id="Narr_0xQ3XrKesES4YvIKRmMegg"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">Beltsville</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_ApHjt-_Wv0eeuVYNQjKXFg"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">Maryland</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:EntityAddressPostalZipCode" id="Tc_gsY_iJSf5E-8g8CzXQqxvw_1_2"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">20705</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(Address of principal</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(Zip Code)</span></p></td></tr><tr style=""><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">executive offices)</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Registrant's telephone number, including area code: </span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:CityAreaCode" id="Narr_LTA490NVW0-UWPO9Oc9s5g"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:LocalPhoneNumber" id="Narr_xCxGtYLt-ku1vElDwKHdPw"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">399-4900</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(Former name or former address, if changed since last report.)</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_o_kf_H9j7UeHBpn3CTrFhw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Wingdings';font-size:10pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_RLPEr9i90kCeq5_ipYGAsQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Wingdings';font-size:10pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_xXp9giAgGUWn8FKNQu91cw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Wingdings';font-size:10pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_w1ft_7w8Wkijm-e5jh4KPw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Wingdings';font-size:10pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.7pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Securities registered pursuant to Section 12(b) of the Act:</span></p><a id="_6dbbe4be_96f8_4435_8798_5ad7ad542be8"></a><a id="Tc_8H1rT2yD-0qoa0D35DW0nw_2_0"></a><a id="Tc_5aP0gjZgRke8VCA54SpIhg_2_1"></a><a id="Tc_t0mSFSFL80ibhKQI_5qAwg_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.76%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.37%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:48.76%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;min-height:0.0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:13.37%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;min-height:0.0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;min-height:0.0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:48.76%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;min-height:9.65pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:13.37%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;min-height:9.65pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:37.86%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;min-height:9.65pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style=""><td style="vertical-align:top;width:48.76%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;min-height:9.65pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:Security12bTitle" id="Tc_s-o4CRRJXEe7CFle7UOi-A_3_0"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:13.37%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;min-height:9.65pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" name="dei:TradingSymbol" id="Tc_hBFpNpgY9kin5mnKLbalMg_3_1"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;">NXTC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:37.86%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;min-height:9.65pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_cIWr8qd4fU6JsdDgrIF0pQ_3_2"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> </span><ix:nonNumeric contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_CZlh9vkalEi94nfd48RN4Q"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Wingdings';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_6558c87f_a572_4428_a136_cef5ebf21930"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 2.02</b></span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Results of Operations and Financial Condition</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">On March 5, 2026, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';">NextCure, Inc. (the &#8220;Company&#8221;)</span><span style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> issued a press release announcing its financial results for the year ended December31, 2025.  The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8221;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.26;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.26;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;visibility:hidden;">&#8203;</span></p><a id="_d1ca8673_a289_44a7_b4ad_afb897d03c6e"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01</b></span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Financial Statements and Exhibits</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(d) Exhibits</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;white-space:pre-wrap;">Exhibit No.    Description</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="nxtc-20260305xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">99.1</span></a></span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;white-space:pre-wrap;">         </b><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="nxtc-20260305xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release issued by NextCure, Inc. dated March 5, 2026</span></a><span style="display:inline-block;width:23.89pt;"></span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;white-space:pre-wrap;">         </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">104</span></span><span style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">         Cover Page Interactive Data File (formatted as inline XBRL).</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_5731e566_c168_487f_9772_480c07da3789"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">November</span></p></div></div></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Dated: March 5, 2026</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NEXTCURE, INC.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">By:          </span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;"> /s/ Steven P. Cobourn                  </span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Name:</span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Steven P. Cobourn</span></p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Title:</span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Chief Financial Officer </span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nxtc-20260305xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/5/2026 06:17:29 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.25;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;"><a name="_Hlk213067541"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';"><img src="nxtc-20260305xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:23.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:134.25pt;"></font><font style="display:inline-block;width:9pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.25;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;">NextCure Provides Business Update and </b></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;">Reports Full Year 2025 Financial Results</b></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;line-height:1.38;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:12pt;line-height:1.19;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8211;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;font-weight:normal;">Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8211;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:italic;font-weight:normal;">LNCB74 Phase 1 dose escalation trial update planned in second half of 2026</i></td></tr></table><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;line-height:1.38;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">BELTSVILLE, MD</b><font style="font-family:'Calibri','Helvetica','sans-serif';"> </font><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#8211; March 5, 2026 </b><font style="font-family:'Calibri','Helvetica','sans-serif';">(GLOBE NEWSWIRE) </font><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#8211;</b><font style="font-family:'Calibri','Helvetica','sans-serif';"> </font><u style="color:#467886;font-family:'Calibri','Helvetica','sans-serif';text-decoration-line:underline;text-decoration-style:solid;">NextCure, Inc.</u><font style="font-family:'Calibri','Helvetica','sans-serif';"> (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2025 financial results.</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;2026 is on track to be transformational for NextCure, as we set the stage to present clinical dose escalation data from the Phase 1 trial for SIM0505, in development for multiple cancers,&#8221; said Michael Richman, President and CEO of NextCure. &#8220;Since acquiring the program in June of 2025, we have made rapid clinical and regulatory progress and soon expect to begin enrolling platinum resistant ovarian cancer patients in the Phase 1 dose optimization study. To accelerate the program, we plan to double the number of U.S. trial sites and expand our footprint into multiple other countries.&#8221;</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.38;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Business Highlights and Near-Term Milestones</b></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;line-height:1.38;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">SIM0505 (CDH6 ADC): Phase 1 dose escalation data expected in Q2 2026</b></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">SIM0505 is a novel ADC directed to cadherin-6 (CDH6 ADC), overexpressed in several cancers including ovarian cancer, with limited expression in healthy tissues. SIM0505 features a proprietary topoisomerase 1 inhibitor (TOPOi) payload, designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. </font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Data from the Phase 1 open-label dose escalation study is expected to be presented in the second quarter of 2026, including results from patients in the U.S. and China. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">The study (</font><u style="color:#467886;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-line:underline;text-decoration-style:solid;">NCT06792552</u><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">) is evaluating SIM0505 in patients with advanced solid tumors with a focus on gynecological cancers and an emphasis on platinum resistant ovarian cancer (PROC).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Initiation of Phase 1 dose optimization study in ovarian cancer expected in the second quarter of 2026 with a continued focus on PROC. The Company anticipates doubling the number of trial sites in the second half of 2026, including the activation of sites in Canada and Europe, with continued study site additions in 2027.</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.41%;margin-right:9.41%;margin-top:30pt;page-break-after:always;width:81.18%;border-width:0;"><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">LNCB74 (B7-H4 ADC): Ongoing enrollment in Phase 1 dose escalation </b></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">LNCB74 is a novel ADC directed to B7-H4, overexpressed in several cancers, with limited expression in healthy tissues. LNCB74 features a proprietary tumor-selective cleavable linker and a tubulin inhibitor monomethyl auristatin E (MMAE) payload.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Higher dose cohort enrollment initiated in the ongoing open-label Phase 1 dose escalation study (</font><u style="color:#467886;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-line:underline;text-decoration-style:solid;">NCT06774963</u><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">), following the November 2025 protocol amendment announcement. The next dose cohort will prioritize patients with high B7-H4 expression in breast and gynecological cancers, as well as the inclusion of patients with adenoid cystic carcinoma type 1.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">NextCure continues to plan to provide a trial update in the second half of 2026.</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;line-height:1.38;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Financial Results for the Full Year Ended December 31, 2025</b></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;line-height:1.38;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Cash, cash equivalents, and marketable securities as of December 31, 2025 were $41.8 million as compared to $68.6 million as of December 31, 2024. The decrease of $26.8 million was primarily due to cash used to fund operations of $49.6 million, including $13.5 million of upfront license fees and milestone payments to Simcere Zaiming </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Pharmaceutical Co., Ltd. </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">for the rights to SIM0505, </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">partially offset by proceeds of $22.3 million from equity sales including a $21.5 million private placement of common stock in November 2025.  NextCure expects current financial resources to be sufficient to fund operating expenses and capital expenditures into the first half of 2027 through proof-of-concept for SIM0505.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Research and development expenses were $44.9 million for the full year ended December 31, 2025, as compared to $41.5 million for the full year ended December 31, 2024.  The increase of $3.4 million was due to $18.5 million of license fees and milestone payments for SIM0505 partially offset by lower costs related to deprioritized programs, lower preclinical development costs and lower personnel-related costs.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:12pt;line-height:1.19;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">General and administrative expenses were $12.7 million for the full year ended December 31, 2025, as compared to $15.7 million for the full year ended December 31, 2024. The decrease of $3.0 million was primarily related to lower </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;background:#ffffff;">personnel costs.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Net loss was </font><font style="font-family:'Aptos';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_Hlk101268176"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">$55.8 million for the full year ended December 31, 202</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">5, as compared to a net loss of $55.7 million for the full year ended December 31, 2024.  Net loss for the year ended December 31, 2025 was driven by higher research and development costs and lower other income of $2.3 million, partially offset by lower general and administrative costs and lower restructuring charges.</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Aptos';font-size:12pt;line-height:1.25;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.38;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About SIM0505</b></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">SIM0505 is a novel antibody drug conjugate (ADC) directed to cadherin-6 (CDH6 ADC), featuring a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ADC is designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. SIM0505 is being evaluated in an open-label, Phase 1 study for the potential treatment of advanced solid tumors, including ovarian cancer, with an emphasis on platinum resistant ovarian cancer. NextCure holds </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.41%;margin-right:9.41%;margin-top:30pt;page-break-after:always;width:81.18%;border-width:0;"><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">exclusive global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan which are retained by Simcere Zaiming Pharmaceutical Co., Ltd.</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About LNCB74</b></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">LNCB74 is a novel antibody drug conjugate (ADC) directed to B7-H4, featuring a proprietary tumor-selective cleavable linker and a tubulin inhibitor monomethyl auristatin E (MMAE) payload. LNCB74 is being evaluated in an open-label, Phase 1 dose escalation study for the potential treatment of advanced solid tumors. NextCure shares global co-development rights with LigaChem Biosciences, Inc. through a 50-50 cost share arrangement.</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About NextCure, Inc.</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">NextCure is a clinical-stage biopharmaceutical company focused on advancing innovative medicines to treat cancer patients through the use of targeted therapies including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells within and beyond the tumor microenvironment, and the role each interaction plays in a biologic response.</font><font style="font-family:'Times New Roman','Times','serif';"> </font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;padding-bottom:10pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;padding-bottom:8pt;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim&#8221;, &#8220;anticipate&#8221;, &#8220;assume&#8221;, &#8220;believe&#8221;, &#8220;continue&#8221;, &#8220;could&#8221;, &#8220;should&#8221;, &#8220;due&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;hope&#8221;, &#8220;may&#8221;, &#8220;objective&#8221;, &#8220;plan&#8221;, &#8220;predict&#8221;, &#8220;potential&#8221;, &#8220;positioned&#8221;, &#8220;seek&#8221;, &#8220;target&#8221;, &#8220;towards&#8221;, &#8220;forward&#8221;, &#8220;later&#8221;, &#8220;will&#8221;, &#8220;would&#8221;, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.38;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: market and other conditions; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure&#8217;s limited operating history and not having any products approved for commercial sale; NextCure&#8217;s history of significant losses; NextCure&#8217;s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; NextCure&#8217;s reliance upon collaborators and international vendors for advancing clinical programs; NextCure&#8217;s ability to maintain listing of its common stock on the Nasdaq Global Select Market; and NextCure&#8217;s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure&#8217;s actual results are described under the heading &#8220;Risk Factors&#8221; in NextCure&#8217;s most recent Annual Report on Form 10-K and in NextCure&#8217;s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:9.41%;margin-right:9.41%;margin-top:30pt;page-break-after:always;width:81.18%;border-width:0;"><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:100%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">NextCure, Inc.</b></p></td></tr><tr style=""><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:100%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Selected Financial Information</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Selected Statement of Operations Items:</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Year Ended </b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">(in thousands, except share and per share amounts)</i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Operating expenses: </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;">  Research and development</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 44,923</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 41,488</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;">  General and administrative</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 12,693</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 15,718</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;">  Restructuring and asset impairment</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 2,542</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Loss from operations</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(57,616)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(59,748)</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Other income, net</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 1,772</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">4,094 </font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Net loss</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(55,844)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(55,654)</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Net loss per common share - basic and diluted (1)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> (19.65)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> (23.88)</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Weighted-average shares outstanding - basic and diluted</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">2,842,448 </font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">2,330,386 </font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(1) -- Net loss per common share for 2024 has been restated to reflect the impact of the one-for-twelve reverse stock split effectuated on July 14, 2025.</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Selected Balance Sheet Items:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Cash, cash equivalents, and marketable securities</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 41,818</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 68,621</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Total assets</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 50,183</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 80,860</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Accounts payable and accrued liabilities</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 10,566</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 9,574</font></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Total stockholders&#39; equity</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 34,943</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';white-space:pre-wrap;"> 65,472</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:12pt;line-height:1.38;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Investor Inquiries</b></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Timothy Mayer, Ph.D.</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">NextCure, Inc.</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Chief Operating Officer</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(240) 762-6486</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><u style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;">IR@nextcure.com</u></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.38;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Mike Moyer</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Managing Director, </font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">LifeSci Advisors, LLC</font></p><p style="font-family:'Aptos';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Phone: (617) 308-4306</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><u style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#0563c1;text-decoration-line:underline;text-decoration-style:solid;">mmoyer@lifesciadvisors.com</u></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:9.41%;margin-right:9.41%;margin-top:30pt;page-break-after:avoid;width:81.18%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>nxtc-20260305xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20260305xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  O 0T# 2(  A$! Q$!_\0
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M=AUC2)8H;Z$,J231"0#(P>#7HW_#6OQ''']KV/T^Q1U69TLRJ3BL%)1BOO\
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M\DC!?/XS'-CU90<^X/K7CL__  4)^(EQ#)$_[/>O%'4J1NN>A_[=J^./"_\
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M7SN)K2:MB9)17V8]?4^_P.54<+/VM*\Y_P TNGHNA[G^RU\6O&?QZ^"L^O\
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B^%8+>"/HJCU/<GJ3W))KEK4H4DH\UY=>R-:<Y3=[:'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nxtc-20260305.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/5/2026 6:17:33 PM-->
<!--Modified on: 3/5/2026 6:17:33 PM-->
<xsd:schema targetNamespace="http://nextcure.com/20260305" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:nxtc="http://nextcure.com/20260305" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://nextcure.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20260305_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20260305_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20260305_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>nxtc-20260305_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/5/2026 6:17:33 PM-->
<!--Modified on: 3/5/2026 6:17:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="nxtc-20260305.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>nxtc-20260305_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/5/2026 6:17:33 PM-->
<!--Modified on: 3/5/2026 6:17:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>nxtc-20260305_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/5/2026 6:17:33 PM-->
<!--Modified on: 3/5/2026 6:17:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="nxtc-20260305.xsd#DocumentDocumentAndEntityInformation" roleURI="http://nextcure.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://nextcure.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639083314537818634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_639083314537818634" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639083314537818634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639083314537818634" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639083314537818634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_639083314537818634" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639083314537818634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639083314537818634" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639083314537818634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_639083314537818634" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639083314537818634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639083314537818634" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639083314537818634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639083314537818634" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_639083314537818634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_639083314537818634" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639083314537818634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639083314537818634" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_639083314537818634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_639083314537818634" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_639083314537818634" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_639083314537818634" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639083314537976357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_639083314537976357" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639083314537976738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_639083314537976738" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_639083314537978023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications_639083314537978023" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_639083314537978023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial_639083314537978023" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_639083314537978023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_639083314537978023" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_639083314537978023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_639083314537978023" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639083314537978023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_639083314537978023" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639083314537978023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_639083314537978023" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_639083314537983254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_639083314537983254" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639083314537983254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639083314537983254" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639083314537983254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639083314537983254" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639083314537983254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_639083314537983254" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 05, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  05,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NextCure, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5231247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9000 Virginia Manor Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Beltsville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">399-4900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NXTC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001661059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nxtc-20260305x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nextcure.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nxtc-20260305.xsd</File>
    <File>nxtc-20260305_def.xml</File>
    <File>nxtc-20260305_lab.xml</File>
    <File>nxtc-20260305_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="nxtc-20260305x8k.htm">nxtc-20260305x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nxtc-20260305x8k.htm": {
   "nsprefix": "nxtc",
   "nsuri": "http://nextcure.com/20260305",
   "dts": {
    "schema": {
     "local": [
      "nxtc-20260305.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "nxtc-20260305_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nxtc-20260305_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nxtc-20260305_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "nxtc-20260305x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://nextcure.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nxtc-20260305x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nxtc-20260305x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-26-024121-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-024121-xbrl.zip
M4$L#!!0    ( /:!95R&[SL8=P,  + -   1    ;GAT8RTR,#(V,#,P-2YX
M<V3=5MMNVS@0?2^P_\#J7:)DK[.-D;AHFA8HD'2+M 7R5M#2V"&6(K4D5;M_
MWR$ERI?(LHWN HM]LCQSYLR%,T->O5Z7@GP';;B2UU&6I!$!F:N"R^5U5-M%
M_"IZ/?OMQ=7+.'Z\>;@CA<KK$J0EN09FH2 K;I_(%U553))[T)H+06XT+Y9
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M[0VW7=EDS]*VET>R=7N<_ %02P,$%     @ ]H%E7->B5=+(!0  9$,  !4
M  !N>'1C+3(P,C8P,S U7VQA8BYX;6S5F^%OXC88QK]7VO_PCGW9I LTH-Y6
MU')JN=X)K;VB@VFG3=,I) :B!1LYIL!_/]N)@8 =*)3,^7*7\CYY_+SF=XF=
MYFX^+"81O" :AP3?5MSJ9040]DD0XM%M9<:&SF^5#ZT?+FY^=)QO]U\?(2#^
M;((P Y\BCZ$ YB$;0Y],IQZ&)T1I&$5P3\-@A !<MUJO7E:OP'%:TN+>B_DI
M!(/TJE==56BG;@0WH5&[JM4OZ^_A?=/]M=EH0/=)R9YXL&&X1Q>%^-^F^&/
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MO&'W&(>]36:8T66;!&8"]YUE.Y '=9WE,_<4FW$]+/B)]&8&>0=R&" 4TJ%
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M>D9EQH_9:"M(&2G_1F"5\IG"JZ#K7%YX\PR^GN1@2AOS&=[[[2&96TF,/E@
M7C$N'BP@+Q47CRNLB*3F]R>AQBVBTX57/X]/&E[=@&J#WYRT.D.?A#KKHHTZ
M2QLUDZ-DW][AABUZH'IT#)?118:-@^#!6SIC\=X1;6M$\S%+XT<NVSZMU7GH
M+MQ("^U(MBV2U>.#J9B8D<2W!&=EV+7@EZE',TO*G1+]X^C-PZF[N<*)V%<=
M"Z+.%.RDB#C@7+G<:'RZJY)\^=0F^=LKBRO%^T/7$0M1&6@T7 2\U0Q=X_X
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MPAP2%H0 M[#-$1(G2'QD%PZTA"X78"'@0 XCB;!+><+-0TH)/DUR*6!,@/J
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MR[V-YW($RL6D%0#L7(:O7(G &9ZF I\%F,_P@=E*A]8MF6/3?#WK@%NH/3>
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MJVT=M=9V1,3C.O6VV<PYF/?5']OEQ,QK1:!T.J^HVIJ/U)$DXX[TI=MTLP)
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M 5!+ 0(4 Q0    ( /:!95R&[SL8=P,  + -   1              "  0
M  !N>'1C+3(P,C8P,S U+GAS9%!+ 0(4 Q0    ( /:!95QX0 _YY@(  " +
M   5              "  :8#  !N>'1C+3(P,C8P,S U7V1E9BYX;6Q02P$"
M% ,4    " #V@65<UZ)5TL@%  !D0P  %0              @ &_!@  ;GAT
M8RTR,#(V,#,P-5]L86(N>&UL4$L! A0#%     @ ]H%E7!2;Q8^8!   8BP
M !4              ( !N@P  &YX=&,M,C R-C S,#5?<')E+GAM;%!+ 0(4
M Q0    ( /:!95PA0TBJ6!4  !>T   4              "  841  !N>'1C
M+3(P,C8P,S U>#AK+FAT;5!+ 0(4 Q0    ( /:!95P<,U1!(!H  &89 0 8
M              "  0\G  !N>'1C+3(P,C8P,S U>&5X.3ED,2YH=&U02P4&
2      8 !@"0 0  94$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>nxtc-20260305x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nxtc-20260305.xsd" xlink:type="simple"/>
    <context id="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2026-03-05</startDate>
            <endDate>2026-03-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Tc_XOUQAewLeUi6qi4jS3fdZg_2_1">0001661059</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Tc_Q4u6uM_Cx0uRN9GIvwlpxw_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_rBxf571z-U6EaCD5I0OPUw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_Lh3CRSkCfUO-ZoABJF3n1A">2026-03-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_l_31-DbIIE2SDlzdoN6r_g">NextCure, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_V05w5aT3xku3LA1ofChQbw">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr__7d_6k6HF0ud4cfvZ5JU3g">001-38905</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_RMGyzKYe9Uu8OMME6m-JCw">47-5231247</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_sduoItm1wUiPpilFpD3d-w">9000 Virginia Manor Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_XgT7Mx21XEOOY9bwaPMDDA">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_0xQ3XrKesES4YvIKRmMegg">Beltsville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_ApHjt-_Wv0eeuVYNQjKXFg">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Tc_gsY_iJSf5E-8g8CzXQqxvw_1_2">20705</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_LTA490NVW0-UWPO9Oc9s5g">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_xCxGtYLt-ku1vElDwKHdPw">399-4900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_o_kf_H9j7UeHBpn3CTrFhw">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_RLPEr9i90kCeq5_ipYGAsQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_xXp9giAgGUWn8FKNQu91cw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_w1ft_7w8Wkijm-e5jh4KPw">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Tc_s-o4CRRJXEe7CFle7UOi-A_3_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Tc_hBFpNpgY9kin5mnKLbalMg_3_1">NXTC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Tc_cIWr8qd4fU6JsdDgrIF0pQ_3_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_3_5_2026_To_3_5_2026_gQDw9vk4cU63SIyTRPB0AA"
      id="Narr_CZlh9vkalEi94nfd48RN4Q">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
